JP2009522244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522244A5 JP2009522244A5 JP2008548029A JP2008548029A JP2009522244A5 JP 2009522244 A5 JP2009522244 A5 JP 2009522244A5 JP 2008548029 A JP2008548029 A JP 2008548029A JP 2008548029 A JP2008548029 A JP 2008548029A JP 2009522244 A5 JP2009522244 A5 JP 2009522244A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- aziridin
- hydroxylamino
- nitrobenzamide
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 238000000034 method Methods 0.000 claims 17
- OAALBIMEFVOQBY-UHFFFAOYSA-N 5-(aziridin-1-yl)-4-(hydroxyamino)-2-nitrobenzamide Chemical compound C1=C([N+]([O-])=O)C(C(=O)N)=CC(N2CC2)=C1NO OAALBIMEFVOQBY-UHFFFAOYSA-N 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 11
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- 239000000725 suspension Substances 0.000 claims 7
- WOCXQMCIOTUMJV-UHFFFAOYSA-N cb1954 Chemical compound C1=C([N+]([O-])=O)C(C(=O)N)=CC(N2CC2)=C1[N+]([O-])=O WOCXQMCIOTUMJV-UHFFFAOYSA-N 0.000 claims 6
- 229940120503 dihydroxyacetone Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000035755 proliferation Effects 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229950010880 tretazicar Drugs 0.000 claims 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- -1 chloro, bromo, iodo Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- UQPHVQVXLPRNCX-UHFFFAOYSA-N erythrulose Chemical compound OCC(O)C(=O)CO UQPHVQVXLPRNCX-UHFFFAOYSA-N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000000443 aerosol Substances 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 150000002828 nitro derivatives Chemical class 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- OEWYWFJWBZNJJG-UHFFFAOYSA-N 1-(aziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CC1 OEWYWFJWBZNJJG-UHFFFAOYSA-N 0.000 claims 2
- LQYDLQVLLUVETH-UHFFFAOYSA-N 5-(aziridin-1-yl)-2-(hydroxyamino)-4-nitrobenzamide Chemical compound C1=C(NO)C(C(=O)N)=CC(N2CC2)=C1[N+]([O-])=O LQYDLQVLLUVETH-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 229930192627 Naphthoquinone Natural products 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000000260 Warts Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims 2
- 150000004056 anthraquinones Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000006227 byproduct Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 150000002791 naphthoquinones Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- 201000010153 skin papilloma Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 claims 2
- TYHFGYCQFVYKHS-UHFFFAOYSA-N 1-(2-bromoethylamino)-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound BrCCNCC(O)CN1C=CN=C1[N+]([O-])=O TYHFGYCQFVYKHS-UHFFFAOYSA-N 0.000 claims 1
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 claims 1
- IELUEMDLMLUMTE-UHFFFAOYSA-N 4-(hydroxyamino)-2-nitrobenzamide Chemical compound NC(=O)C1=CC=C(NO)C=C1[N+]([O-])=O IELUEMDLMLUMTE-UHFFFAOYSA-N 0.000 claims 1
- MXPOCMVWFLDDLZ-UHFFFAOYSA-N 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-(3-hydroxyprop-1-enyl)-1-methylindole-4,7-dione Chemical compound CN1C(C=CCO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 claims 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 claims 1
- 206010056474 Erythrosis Diseases 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 claims 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 1
- 229960005091 chloramphenicol Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 claims 1
- 229950010514 misonidazole Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 229960001907 nitrofurazone Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 231100000065 noncytotoxic Toxicity 0.000 claims 1
- 230000002020 noncytotoxic effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- GUEIZVNYDFNHJU-UHFFFAOYSA-N quinizarin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=CC=C2O GUEIZVNYDFNHJU-UHFFFAOYSA-N 0.000 claims 1
- 125000004151 quinonyl group Chemical group 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526552.5 | 2005-12-29 | ||
| GB0526552A GB0526552D0 (en) | 2005-12-29 | 2005-12-29 | New use |
| PCT/GB2006/004947 WO2007074344A1 (en) | 2005-12-29 | 2006-12-29 | Use of alpha-hydroxy carbonyl compounds as reducing agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013015431A Division JP5699170B2 (ja) | 2005-12-29 | 2013-01-30 | α−ヒドロキシカルボニル化合物の還元剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009522244A JP2009522244A (ja) | 2009-06-11 |
| JP2009522244A5 true JP2009522244A5 (enExample) | 2010-02-18 |
| JP5368803B2 JP5368803B2 (ja) | 2013-12-18 |
Family
ID=35841324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008548029A Active JP5368803B2 (ja) | 2005-12-29 | 2006-12-29 | α−ヒドロキシカルボニル化合物の還元剤としての使用 |
| JP2013015431A Active JP5699170B2 (ja) | 2005-12-29 | 2013-01-30 | α−ヒドロキシカルボニル化合物の還元剤としての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013015431A Active JP5699170B2 (ja) | 2005-12-29 | 2013-01-30 | α−ヒドロキシカルボニル化合物の還元剤としての使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9029569B2 (enExample) |
| EP (2) | EP2258430B1 (enExample) |
| JP (2) | JP5368803B2 (enExample) |
| KR (1) | KR20080091354A (enExample) |
| CN (4) | CN107080746B (enExample) |
| AU (1) | AU2006329678B2 (enExample) |
| CA (2) | CA2635388C (enExample) |
| ES (2) | ES2399288T3 (enExample) |
| GB (1) | GB0526552D0 (enExample) |
| IL (1) | IL192507A0 (enExample) |
| MX (1) | MX2008008616A (enExample) |
| NO (1) | NO20082852L (enExample) |
| NZ (1) | NZ569483A (enExample) |
| RU (2) | RU2445078C2 (enExample) |
| WO (1) | WO2007074344A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| JP5570996B2 (ja) | 2007-12-14 | 2014-08-13 | エアロデザインズ インコーポレイテッド | エアロゾル化可能な食料品の送達 |
| AU2009304542A1 (en) * | 2008-10-15 | 2010-04-22 | Xingnong Wang | Use of tetrose to inhibit cancer and to increase cell viability |
| US20110216880A1 (en) * | 2010-03-05 | 2011-09-08 | General Electric Company | System and method for molecular breast imaging |
| US8691198B2 (en) * | 2010-06-25 | 2014-04-08 | Somogyi Agtech Llc | Environmentally benign plasticizers based on derivatives of acetone |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3208999A (en) | 1964-09-09 | 1965-09-28 | Nat Starch Chem Corp | Preparation of non-inhibited starch amines |
| US3658788A (en) * | 1969-06-06 | 1972-04-25 | Salk Inst For Biological Studi | Aminooxazolines and products thereof and processes for synthesizing same |
| US3711602A (en) * | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
| JPS52145523A (en) * | 1976-05-28 | 1977-12-03 | Kouki Yagishita | Antiitumor agent |
| DE2730720C2 (de) * | 1977-07-07 | 1979-07-12 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von praktisch reinem l-Amino-8-nitro-43dihydroxy-anthrachinon |
| CA1089763A (en) | 1978-10-30 | 1980-11-18 | Willard J. Johnson | Rodenticide comprising 6-aminonicotinamide and 6- aminonicotinohydroxamic acid |
| CS204501B1 (en) | 1978-11-06 | 1981-04-30 | Miroslav Dub | Shaped trap for regulation of the numbers of exoantropous and hemisynantropous rodents classes |
| US4375394A (en) * | 1982-03-11 | 1983-03-01 | Eastman Kodak Company | Electrolytic process for the preparation of ethylene glycol and glycerine |
| ATE66375T1 (de) * | 1984-10-05 | 1991-09-15 | Bioferon Biochem Substanz | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| GB8804068D0 (en) * | 1988-02-22 | 1988-03-23 | Roberts J R | Improvements relating to control of neoplastic tissue growth |
| CH680180B5 (enExample) | 1988-07-29 | 1993-01-15 | Ciba Geigy Ag | |
| DE3833194A1 (de) | 1988-09-30 | 1990-04-05 | Basf Ag | Verfahren zum faerben von textilen materialien aus cellulosefasern |
| DE4103639A1 (de) * | 1991-02-07 | 1992-08-13 | Basf Ag | Verfahren zum faerben von textilen materialien aus cellulosefasern |
| AU681337B2 (en) | 1991-10-23 | 1997-08-28 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form |
| GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| DE4425436A1 (de) * | 1994-07-19 | 1996-01-25 | Basf Ag | Verfahren zur Herstellung von Acyloinen |
| GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
| US5632782A (en) * | 1994-09-01 | 1997-05-27 | Clariant Finance (Bvi) Ltd. | Exhaust dyeing process for sulphur dyes |
| US20040053208A1 (en) | 1995-08-29 | 2004-03-18 | V. I. TECHNOLOGIES, Inc. | Methods to selectively inactivate parasites in biological compositions |
| WO1997023456A1 (en) | 1995-12-21 | 1997-07-03 | British Technology Group Ltd. | Indoloquinone derivatives as bioreductive agents |
| NZ336381A (en) * | 1996-12-30 | 2000-11-24 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| WO1998035701A1 (en) | 1997-02-11 | 1998-08-20 | Theramark Limited | Drug targeting |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| GB9712370D0 (en) * | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| GB2365338B (en) | 1997-06-14 | 2002-04-03 | Enzacta R & D Ltd | Therapeutic systems |
| US6159706A (en) | 1997-12-23 | 2000-12-12 | Newbiotics, Inc. | Application of enzyme prodrugs as anti-infective agents |
| HRP20000794A2 (en) | 1998-05-22 | 2001-10-31 | Shionogi Biores Corp | Bioreductive cytotoxic agents |
| JP2002523382A (ja) | 1998-08-19 | 2002-07-30 | ザ・ビクトリア・ユニバーシテイ・オブ・マンチエスター | 薬物ターゲティング |
| WO2001036007A2 (en) * | 1999-11-12 | 2001-05-25 | Angiotech Pharmaceuticals, Inc. | Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| HK1053845A1 (zh) | 2000-03-02 | 2003-11-07 | Ml Laboratories Plc | Tcf應答成分 |
| HUP0301120A2 (hu) * | 2000-06-22 | 2003-08-28 | Pfizer Products Inc. | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények |
| DE10049468A1 (de) * | 2000-10-06 | 2002-04-11 | Bayer Ag | N-Alkoxyalkyl-substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen |
| EP1355566B1 (en) * | 2000-12-18 | 2012-11-28 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
| US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
| GB0223696D0 (en) | 2002-10-14 | 2002-11-20 | Ml Lab Plc | Improved immunotherapy |
| GB0313604D0 (en) * | 2003-06-12 | 2003-07-16 | Britannia Pharmaceuticals Ltd | Delivery device for powdered medicament |
| DE102004009434A1 (de) * | 2004-02-24 | 2005-12-15 | Boehringer Ingelheim International Gmbh | Zerstäuber |
| FR2871697B1 (fr) | 2004-06-17 | 2007-06-29 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile |
| CA2570245A1 (en) | 2004-07-02 | 2006-01-12 | Warner-Lambert Company Llc | Compositions and methods for treating pathological infections |
| GB0517957D0 (en) | 2005-09-03 | 2005-10-12 | Morvus Technology Ltd | Method of combating infection |
| GB0526552D0 (en) | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
-
2005
- 2005-12-29 GB GB0526552A patent/GB0526552D0/en not_active Ceased
-
2006
- 2006-12-29 JP JP2008548029A patent/JP5368803B2/ja active Active
- 2006-12-29 EP EP10075381.3A patent/EP2258430B1/en active Active
- 2006-12-29 RU RU2008131054/15A patent/RU2445078C2/ru not_active IP Right Cessation
- 2006-12-29 EP EP06831498A patent/EP1951213B1/en active Active
- 2006-12-29 AU AU2006329678A patent/AU2006329678B2/en active Active
- 2006-12-29 NZ NZ56948306A patent/NZ569483A/xx not_active IP Right Cessation
- 2006-12-29 ES ES06831498T patent/ES2399288T3/es active Active
- 2006-12-29 CN CN201710224938.5A patent/CN107080746B/zh active Active
- 2006-12-29 CN CN201410341330.7A patent/CN104188943B/zh active Active
- 2006-12-29 WO PCT/GB2006/004947 patent/WO2007074344A1/en not_active Ceased
- 2006-12-29 CN CN201310241391.1A patent/CN103315995B/zh active Active
- 2006-12-29 CA CA2635388A patent/CA2635388C/en active Active
- 2006-12-29 ES ES10075381.3T patent/ES2623857T3/es active Active
- 2006-12-29 CN CN200680053566.4A patent/CN101389320B/zh active Active
- 2006-12-29 KR KR20087018577A patent/KR20080091354A/ko not_active Ceased
- 2006-12-29 CA CA2826746A patent/CA2826746C/en active Active
- 2006-12-29 US US12/159,363 patent/US9029569B2/en active Active
- 2006-12-29 MX MX2008008616A patent/MX2008008616A/es active IP Right Grant
-
2008
- 2008-06-27 NO NO20082852A patent/NO20082852L/no not_active Application Discontinuation
- 2008-06-29 IL IL192507A patent/IL192507A0/en unknown
-
2011
- 2011-11-16 RU RU2011146556/15A patent/RU2011146556A/ru not_active Application Discontinuation
-
2013
- 2013-01-30 JP JP2013015431A patent/JP5699170B2/ja active Active
-
2015
- 2015-02-23 US US14/628,980 patent/US9907784B2/en active Active
-
2018
- 2018-01-19 US US15/875,230 patent/US10398676B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2715926T3 (es) | Compuestos para el tratamiento del cáncer | |
| JP2008511601A5 (enExample) | ||
| RU2502730C2 (ru) | Сульфонамидные соединения и их применение | |
| CA2055859A1 (fr) | Derives d'oxazolopyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| JP2011524422A5 (enExample) | ||
| JP2001517699A5 (enExample) | ||
| JP2005519083A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| US20160184265A1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| JP2003506354A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2009524675A5 (enExample) | ||
| MX2009000283A (es) | Compuestos quimicos. | |
| TW201036988A (en) | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | |
| CN113966324B (zh) | Notch信号传导途径抑制剂及其在癌症治疗的用途 | |
| JP2022521081A (ja) | Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体 | |
| US20240287048A1 (en) | Substituted acyl sulfonamides for treating cancer | |
| JP2009522244A5 (enExample) | ||
| US9079876B2 (en) | Imidazole derivatives and preparation method and use thereof | |
| JP2007532625A5 (enExample) | ||
| RU2008131054A (ru) | Применение альфа-гидроксикарбонильных соединений в качестве восстанавливающих веществ | |
| WO1998043943A1 (fr) | Derives de 2-phenoxyaniline | |
| JP2017516824A5 (enExample) | ||
| JP2004528293A5 (enExample) | ||
| CN108473449B (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途 |